Lipoproteins and platelets

Lipoproteins and platelets refers to the complex physiological and pathological interaction between circulating lipoproteins and blood platelets, a critical axis in the development of atherothrombosis (PMID: 24657178). Pro-atherogenic lipoproteins, such as oxidized low-density lipoprotein (oxLDL) and lipoprotein(a), bind to specific receptors on the platelet surface, including CD36, LOX-1, and Toll-like receptors (TLRs) (PMID: 17947325, PMID: 11055971). This binding triggers signaling cascades that sensitize platelets, lowering the threshold for activation and promoting a pro-thrombotic state (PMID: 29101263). Conversely, high-density lipoprotein (HDL) is recognized for its potential anti-thrombotic properties, which include inhibiting platelet aggregation and promoting cholesterol efflux (PMID: 23640951). In clinical practice, this system is managed through a combination of lipid-lowering therapies, such as statins and PCSK9 inhibitors, and antiplatelet medications like aspirin and P2Y12 receptor antagonists (StatPearls: Antiplatelet Agents). While not a single molecular target, the lipoprotein-platelet interface is a major focus for reducing the risk of myocardial infarction and stroke in patients with cardiovascular disease. This interaction highlights the intersection of lipid metabolism and hemostasis in vascular health.

Other names

Lipoprotein-platelet interactionLDL-platelet axisLipoprotein-induced platelet activationPlatelet-lipoprotein interface

Reduction of circulating pro-atherogenic lipoprotein levels to decrease platelet sensitization and direct inhibition of platelet aggregation and activation pathways.